PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Adoption of Polymerase Chain Reaction Across Europe Spurred by Potential to Advance Drug Discovery - A significant number of end users in the genomics and proteomics market are now using polymerase chain reaction (PCR) technology. While the conventional PCR technique is well established, end users are also showing increasing interest in real-time PCR
Adoption of Polymerase Chain Reaction Across Europe Spurred by Potential to Advance Drug Discovery

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/03/13 - A significant number of end users in the genomics and proteomics market are now using polymerase chain reaction (PCR) technology. While the conventional PCR technique is well established, end users are also showing increasing interest in real-time PCR.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Continuous innovation is making this technique more user-friendly and efficient. However, costs associated with instrumentation, servicing contracts and reagents remain areas of concern with end users, particularly price-sensitive academics.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), European PCR Reagents Market for Research Applications, finds that the market earned revenues of $302.0 million in 2007 and estimates this to reach $520.0 billion in 2014.

"Within the realm of drug discovery and development, PCR technology can help in unravelling the human genome and detecting infectious and hereditary diseases by supporting the need to consistently produce pure samples of genetic material," notes Frost & Sullivan Research Analyst Bela Sheth. "Recent revolutions in the drug discovery process have been driven by qPCR's ability to provide real-time quantifications of the amount of DNA/RNA amplified."

Advances in PCR technology that permit the amplification of genetic material within a very short period have heightened expectations of greater uses for the technology. Research applications by academia account for over half the use of PCR, with pharma and biotech companies accounting for the remainder in drug discovery applications. The completion of the human genome project and growing interest in molecular diagnostics will sustain growth in the PCR market.

Intensifying competition and price pressure will characterise the conventional PCR reagents market. On the other hand, end users are becoming increasingly familiar with the benefits of using qPCR. However, the high costs associated with instrumentation and reagents are a major concern for end users.

"PCR has a significant impact on genomics and proteomics, with major scientific breakthroughs and value additions changing the paradigm of drug discovery," explains Sheth. "However, the major question gripping the industry is whether these technologies are cost effective. While they hold great promise, their premium pricing does not justify their use in routine processes."

Numerous growth opportunities are envisioned in the competitive PCR market. However, price has always been a sensitive issue with customers. The cost of instrumentation, servicing contracts and reagents has resulted in this technique being expensive. Therefore, strategies such as installing the instrumentation free or with a minimum charge and binding consumers to servicing contract/reagents can be used to induce consumers to use PCR.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European PCR Reagents Market for Research Applications, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

European PCR Reagents Market for Research Applications is part of the Drug Discovery and Diagnostic Technologies Growth Partnership Service programme, which also includes research in the following markets: Contract Research Organisations (CROs) Markets in Europe, Nucleic Acid Isolation Markets in Europe and Advances in Laboratory Automation Markets in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

European PCR Reagents Market for Research Applications - M1F9

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Adoption of Polymerase Chain Reaction Across Europe Spurred by Potential to Advance Drug Discovery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 21 680 3274 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)